Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.

A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.

A syringe is to be obtained by using PTFE for a gasket main body that makes a direct contact with an injection solution and using a slidable silicone rubber at a portion that does not make contact with the injection solution.

A syringe A includes a syringe barrel 1, a gasket 10 press-fitted within the syringe barrel 1, and a plunger rod 5 mounted in the gasket 10. In the gasket 10, a concaved groove 18 is formed over the whole circumference of a slide-contact surface 11 of a main body portion 26 that is formed of a rigid plastic having a drug solution-resistant property against a drug solution 30 to be loaded in the syringe barrel 1 and that is configured to slidingly contact an inner circumferential surface 2 of the syringe barrel 1. In a slide-contact ring 19 that is to be fitted in the concaved groove 18 and that is configured to slidingly contact the syringe barrel inner circumference surface 2, a silicone oil and a spherical ultrahigh molecular weight fine powder are added to a silicone rubber base material 19c.

An implantable medical device for electrical stimulation or sensing includes a body supporting at least one flexible elongate conductor element. The body includes an insulating structure that protects the flexible conductor element(s). The insulating structure is realized from multiple polymer layers wherein at least one of the polymer layers is formed from a polymer blend of a thermoplastic polyurethane material and an isobutylene block copolymer. In one particular embodiment, the insulating structure of the body includes at least a first polymer layer, a second polymer layer and a third polymer layer, where the second polymer layer covers and interfaces to the first polymer layer, and the third polymer layer covers and interfaces to the second polymer layer. The first polymer layer is formed from a thermoplastic polyurethane material. The third polymer layer is formed from an isobutylene block copolymer. The intermediate second polymer layer is compatible with the particular polymers of the first and third polymer layers and is formed from a polymer blend of a thermoplastic polyurethane material and an isobutylene block copolymer.

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras.

A method for fabricating an embodiment of a medical device comprising the steps of: preparing a biodegradable polymeric structure; coating the biodegradable polymeric structure with a polymeric coat including a pharmacological or biological agent; cutting the structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.

A method for fabricating an embodiment of a medical device comprising the steps of: preparing a biodegradable polymeric structure; coating the biodegradable polymeric structure with a polymeric coat including a pharmacological or biological agent; cutting the structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.

One aspect of the present invention relates generally to injectable compositions. In one embodiment, the compositions include 2-hydroxyethyl methacrylate and a dimethacrylate crosslinker. Another aspect of the invention relates generally to methods of using such compositions for thermal ablation and for the occlusion of body vessels.

The present invention relates to a resorbable polymeric mesh implant, that is intended to be used in the reconstruction of soft tissue defects. The mesh implant has at least a first and a second material, wherein the second material is substantially degraded at a later point in time than the first material following the time of implantation. The mesh implant is adapted to have a predetermined modulus of elasticity that gradually is decreased until the mesh implant is completely degraded and subsequently resorbed. Due to the gradual decrease in the modulus of elasticity of the inventive mesh implant, the regenerating tissue may gradually take over the load applied to the tissue defect area. Interstices between individual filaments of multifilaments create a capillary effect for cells within the body.